Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657019 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension in Adults With Binge Eating Disorder (BED)
A Phase 3 study of Binge-Eating Disorder, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
- 20
- Study locations
NCT01657019: Completed Phase 3 study of Binge-Eating Disorder, sponsored by Shire.
NCT01657019 is a Phase 3 study of Binge-Eating Disorder that has completed, run by Shire. The registered enrollment target is 604 participants, below the 1,127-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01657019, a Phase 3 study of Binge-Eating Disorder, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
Conditions Studied
Interventions
- DRUG Lisdexamfetamine dimesylate
Study Locations (20)
California
- Southwestern Research, Inc. - Beverly Hills
- TRIMED Clinical Trials - Corona
- Pharmacology Research Institute - Encino
- Scripps Clinical Research Services - La Jolla
- Pharmacology Research Institute - Los Alamitos
- Pharmacology Research Institute - Newport Beach
- Pacific Research Partners, LLC - Oakland
- Excell Research, Inc - Oceanside
- PCSD - Feighner Research - San Diego
Florida
- Florida Clinical Research - Bradenton
- Gulfcoast Clinical Research - Fort Myers
- Clinical Neuroscience Solutions, Inc - Jacksonville
- Fidelity Clinical Research, Inc - Lauderhill
- Compass Research, LLC - Leesburg
- Florida Clinical Research Center, LLC - Maitland
Colorado
- Western Affiliated Research Institute, Inc - Denver
- Radiant Research, Inc - Denver
Alabama
- Birmingham Research Group - Birmingham
Arizona
- Radiant Research - Tucson
Arkansas
- Clinical Study Centers, LLC - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2012-08-21 |
| Est. Completion | 2014-10-21 |
| Phase | Phase 3 |
What the finished NCT01657019 record still lists
NCT01657019 is an interventional study that assigns participants to a tested intervention. The registered 604 participants enrollment target is mid-sized for trials with a published cap, below the 1,127-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 1 intervention - of which Lisdexamfetamine dimesylate is the first listed.
NCT01657019 names 20 study sites across 6 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01657019 about?
NCT01657019 is a clinical study titled "Open Label Extension in Adults With Binge Eating Disorder (BED)". To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
What is the current status of trial NCT01657019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2012-08-21. Estimated completion is 2014-10-21.
What conditions does trial NCT01657019 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT01657019?
The interventions under investigation include: Lisdexamfetamine dimesylate (DRUG).
Who is sponsoring clinical trial NCT01657019?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01657019 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01657019's enrollment target sits among peer trials
604 3rd of 37 higher than 35 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
RECRUITING · Phase 3
-
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
COMPLETED · Phase 3
-
Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder
RECRUITING · NA
-
Eating Disorders Genetics Initiative 2
RECRUITING
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
-
Project THINK: Trajectories of Health, Ingestive Behaviors, and Neurocognition in Kids
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI